GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (LTS:0JGL) » Definitions » 3-Year Revenue Growth Rate

PCI Biotech Holding ASA (LTS:0JGL) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2023)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA 3-Year Revenue Growth Rate?

PCI Biotech Holding ASA's Revenue per Share for the three months ended in Jun. 2023 was kr0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of PCI Biotech Holding ASA's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, PCI Biotech Holding ASA's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's 3-Year Revenue Growth Rate falls into.



PCI Biotech Holding ASA 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


PCI Biotech Holding ASA  (LTS:0JGL) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


PCI Biotech Holding ASA 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (LTS:0JGL) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (LTS:0JGL) Headlines

No Headlines